These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2530425)

  • 1. Transdermal therapeutic systems and rate controlled drug delivery.
    Yum SI
    Med Prog Technol; 1989; 15(1-2):47-52. PubMed ID: 2530425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of weekly transdermal estradiol controlled delivery system in postmenopausal Chinese.
    Chen GS; Zhang MY; Wang Q; Ye JC
    Zhongguo Yao Li Xue Bao; 1996 Sep; 17(5):407-10. PubMed ID: 9863160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic systems and drug delivery. 3. Transdermal therapeutic systems].
    Davila D; Karleusa-Simanović A; Davila T
    Lijec Vjesn; 1990; 112(7-8):235-43. PubMed ID: 2292898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Transdermal therapeutic systems (TTS)].
    Dittgen M
    Med Monatsschr Pharm; 1998 Dec; 21(12):366-77. PubMed ID: 9868897
    [No Abstract]   [Full Text] [Related]  

  • 5. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice.
    Henzl MR; Loomba PK
    J Reprod Med; 2003 Jul; 48(7):525-40. PubMed ID: 12953327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal therapeutic systems--actual state and future developments.
    Asmussen B
    Methods Find Exp Clin Pharmacol; 1991 Jun; 13(5):343-51. PubMed ID: 1921571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal drug delivery: a review of pharmaceutics, pharmacokinetics, and pharmacodynamics.
    Moore L; Chien YW
    Crit Rev Ther Drug Carrier Syst; 1988; 4(4):285-349. PubMed ID: 3133121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal scopolamine use for post-rhytidectomy sialocele.
    Lapid O; Kreiger Y; Sagi A
    Aesthetic Plast Surg; 2004; 28(1):24-8. PubMed ID: 15116278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing of controlled-release transdermal dosage forms. Product development and clinical trials.
    Shaw JE; Prevo ME; Amkraut AA
    Arch Dermatol; 1987 Nov; 123(11):1548-56. PubMed ID: 2960274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scopolamine bioavailability in combined oral and transdermal delivery.
    Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
    J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Your CE topic (No. 111). Clinical application of transdermal drug delivery systems (Part II).
    Lackner TE
    J Pract Nurs; 1990 Mar; 40(1):42-50. PubMed ID: 2109799
    [No Abstract]   [Full Text] [Related]  

  • 12. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors.
    Gil A; Nachum Z; Dachir S; Chapman S; Levy A; Shupak A; Adir Y; Tal D
    Aviat Space Environ Med; 2005 Aug; 76(8):766-70. PubMed ID: 16110693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
    Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness.
    Wang ET; Zhou DR; He LH
    Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Transdermal therapeutic systems. Possibilities and limitations].
    Groth H; Spuler A; Vetter W
    Dtsch Med Wochenschr; 1988 May; 113(20):819-21. PubMed ID: 3131097
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent developments in drug delivery.
    Rogers JA
    Can J Hosp Pharm; 1982; 35(6):170-4, 196. PubMed ID: 10262189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Transdermal therapeutic systems for drug administration].
    Hupfeld S; Gravem H
    Tidsskr Nor Laegeforen; 2009 Mar; 129(6):532-3. PubMed ID: 19282891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol.
    Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
    Arzneimittelforschung; 1996 Aug; 46(8):766-73. PubMed ID: 9125276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experimental pharmacokinetics of phenazepam during transdermal administration of the therapeutic phenaperkuten system].
    Litvin AA
    Eksp Klin Farmakol; 2004; 67(2):59-62. PubMed ID: 15188765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.